Singapore-Based Innovative Biomedical Start-Up Achieves 'Strategic Triumph' to Conquer Chinese Med-Tech Market

Syntellix AG China Singapore Germany

NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people Syntellix' product approval for China is the largest and most important success in the company's history; product approval in China was the company's most important strategic and operational goal Syntellix had previously already been granted the accelerated 'innovative pathway' by the NMPA due to the exceptional benefits of its products In total, product approvals for Syntellix products have accumulated to date in countries with more than 5.5 billion inhabitants; product approvals had already been achieved in 73 countries and regions on five continents before current success in China Development of the prioritized core markets of China, India, and ASEAN is being carried out via Syntellix Asia Pte Ltd in Singapore as manufacturing facility & sales hub Syntellix Asia Pte Ltd has been supported by the Singapore Economic Development Board (EDB); Syntellix AG targets IPO on the Singapore Exchange (SGX) Syntellix and Syntellix Asia CEO Claassen: "After 7 years of focusing on China, we have achieved what almost everyone considered impossible. As a startup with its operational heart in Singapore, we have written a pioneering story worldwide, whose global medical success can now no longer be stopped. I sincerely thank the Singapore Economic Development Board (EDB) for its far-sighted contribution to the operational and structural foundation of our rollout in Asia by providing expertise and financial support for the establishment and expansion of our production facility in Singapore, which will now also become an Asia-wide and global sales hub as planned."View original content:https://www.prnewswire.co.uk/news-releases/singapore-based-innovative-biomedical-start-up-achieves-strategic-triumph-to-conquer-chinese-med-tech-market-302511787.html